Patents by Inventor Einar Sigurdsson
Einar Sigurdsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11958898Abstract: The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the truncated Asp421 epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.Type: GrantFiled: February 16, 2021Date of Patent: April 16, 2024Assignee: NEW YORK UNIVERSITYInventor: Einar Sigurdsson
-
Publication number: 20210198349Abstract: The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the truncated Asp421 epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.Type: ApplicationFiled: February 16, 2021Publication date: July 1, 2021Applicant: New York UniversityInventor: Einar Sigurdsson
-
Patent number: 10988528Abstract: The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the truncated Asp421 epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.Type: GrantFiled: August 11, 2016Date of Patent: April 27, 2021Assignee: New York UniversityInventor: Einar Sigurdsson
-
Publication number: 20190315841Abstract: The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the truncated Asp421 epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.Type: ApplicationFiled: August 11, 2016Publication date: October 17, 2019Applicant: New York UniversityInventor: Einar Sigurdsson
-
Patent number: 10358503Abstract: The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the {p}Ser404 Epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.Type: GrantFiled: August 11, 2016Date of Patent: July 23, 2019Assignee: New York UniversityInventor: Einar Sigurdsson
-
Publication number: 20180312608Abstract: The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the {p}Ser404 Epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody -based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.Type: ApplicationFiled: August 11, 2016Publication date: November 1, 2018Applicant: New York UniversityInventor: Einar Sigurdsson
-
Patent number: 9139643Abstract: The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.Type: GrantFiled: September 2, 2011Date of Patent: September 22, 2015Assignee: New York UniversityInventors: Einar Sigurdsson, Ayodeji Asuni
-
Publication number: 20110318358Abstract: The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.Type: ApplicationFiled: September 2, 2011Publication date: December 29, 2011Applicant: NEW YORK UNIVERSITYInventors: Einar SIGURDSSON, Ayodeji ASUNI
-
Patent number: 8012936Abstract: The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.Type: GrantFiled: March 29, 2007Date of Patent: September 6, 2011Assignee: New York UniversityInventors: Einar Sigurdsson, Ayodeji Asuni
-
Publication number: 20080050383Abstract: The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.Type: ApplicationFiled: March 29, 2007Publication date: February 28, 2008Applicant: NEW YORK UNIVERSITYInventors: Einar SIGURDSSON, Ayodeji ASUNI
-
Publication number: 20070059807Abstract: Vaccines against prion disease eliciting a humoral immune response when administered mucosally are described. The vaccines comprise a prion protein, a prion protein fragment, or a non-amyloidogenic prion protein homolog and an adjuvant suitable for inducing a humoral immune response after mucosal administration. Suitable adjuvants include cholera toxin subunit B, heat-labile enterotoxin and aluminum hydroxide. Alternatively, the vaccine comprises a vector encoding a prion protein, fragment, or homolog in an attenuated Salmonella host. The vaccines can be used to prevent or treat prion disease in humans and other mammals.Type: ApplicationFiled: May 20, 2004Publication date: March 15, 2007Applicant: New York UniversityInventors: Thomas Wisniewski, Einar Sigurdsson, Jose Chabalgoity, Fernando Goni, Blas Frangione
-
Publication number: 20070010435Abstract: Disclosed herein are methods for treating amyloid disease in humans by clearing amyloid peptides from one or more bodily fluids such as, e.g., blood, of a patient. In particular, the methods are based on the administration capable of binding to amyloid-beta (A?) or on dialysis of blood or plasma exchange in order to remove A? peptides from the blood circulation, and/or brain or other affected organs.Type: ApplicationFiled: December 18, 2003Publication date: January 11, 2007Applicant: NEW YORK UniversityInventors: Blas Frangione, Einar Sigurdsson, Thomas Wisniewski, Jorge Ghiso
-
Patent number: 6821504Abstract: Alzheimer's disease can be diagnosed in vivo using magnetic resonance imaging. A labeled A&bgr; peptide or its derivative is injected into the patient to be diagnosed, after which the patient is subjected to magnetic resonance imaging. Both pre-amyloid and amyloid plaques can be detected using this method.Type: GrantFiled: May 23, 2002Date of Patent: November 23, 2004Assignee: New York UniversityInventors: Thomas Wisniewski, Daniel Turnbull, Einar Sigurdsson, Youssef Zaim Wadghiri